Diclofenac topical - Phosphagenics

Drug Profile

Diclofenac topical - Phosphagenics

Alternative Names: TPM®/diclofenac gel; TPM®/diclofenac transdermal matrix patch; Voveran TPM

Latest Information Update: 16 Jul 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Phosphagenics
  • Developer Nippon Zoki; Novartis; Phosphagenics
  • Class Antipyretics; Antirheumatics; Non-opioid analgesics; Nonsteroidal anti-inflammatories; Phenylacetates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors; Prostaglandin synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Musculoskeletal pain
  • Preclinical Pain

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Musculoskeletal-pain(In volunteers) in Australia (Topical, Gel)
  • 18 May 2016 Phosphagenics expands its existing license agreement with Themis Medicare for diclofenac topical to include territorial rights in Armenia, Belarus, Georgia, Kazakhstan, Kenya, Kyrgyzstan, Moldova, Philippines, Rwanda, Sri Lanka, Tanzania, Turkmenistan, Uganda, Ukraine, Uzbekistan and Vietnam
  • 18 May 2016 Themis announces intention to submit marketing authorisations to Armenia, Belarus, Georgia, Kazakhstan, Kenya, Kyrgyzstan, Moldova, Philippines, Rwanda, Sri Lanka, Tanzania, Turkmenistan, Uganda, Ukraine, Uzbekistan and Vietnam
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top